End-Stage Renal Disease (ESRD) Clinical Trial
Official title:
Improvement of EPO-resistance in HD Patients With Chronic Inflammation by High Cut-off Hemodialysis - Pilot Study (CIEPO-PILOT)
Chronic inflammation in dialysis patients is linked to cardiovascular mortality and clinical signs and symptoms, like the impaired response to erythropoiesis-stimulating agents (ESAs). This study aims to demonstrate that high cut-off hemodialysis is effective in reducing chronic inflammation and thereby improving response to ESAs.
Chronic inflammation in hemodialysis patients (micro-inflammation) is caused by multiple
inflammatory stimuli and becomes apparent by elevated levels of biochemical markers such as
CRP, IL-6, cellular activation markers etc. Chronic inflammation is linked to clinical signs
and symptoms and cardiovascular mortality in dialysis patients. Inflamed dialysis patients
show impaired response to erythropoiesis-stimulating agents (ESA) related to reduced iron
utilization (functional iron deficiency) and elevated CRP levels are associated with a
greater need for ESA to meet hemoglobin targets. If absolute iron deficiency can been
excluded, EPO resistance is likely related to 'inflammatory block'.
The high molecular permeability of the Theralite high cut-off membrane allows for
significant clearance of cytokines and other pro-inflammatory solutes by hemodialysis as
shown in previous trials with high cut-off dialyzers. The study therefore aims to
demonstrate that Theralite dialysis is effective in reducing chronic inflammation in ESRD
patients, thereby improving EPO responsiveness. If this can be demonstrated, application of
Theralite hemodialysis may reduce morbidity and mortality in the long term in ESRD patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02553889 -
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
|
Phase 2 | |
| Completed |
NCT01222234 -
Impact of Vitamin D Therapies on Chronic Kidney Disease
|
N/A | |
| Recruiting |
NCT00243958 -
Aluminum and Auditory Function in ESRD
|
N/A | |
| Active, not recruiting |
NCT03989141 -
Creating a Buttonhole Tunnel Track by Repeated Needling of the AV Fistula on the Same Day in Patients on Hemodialysis.
|
N/A | |
| Completed |
NCT05285787 -
A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
|
Phase 2 | |
| Completed |
NCT05769595 -
Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)
|
Phase 1 | |
| Completed |
NCT03119818 -
Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy
|
N/A | |
| Completed |
NCT01228279 -
Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
|
Phase 4 | |
| Completed |
NCT02502903 -
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders
|
Phase 1 | |
| Enrolling by invitation |
NCT06243900 -
NIRS for the Diagnosis of Residual Renal Function Injury in Hemodialysis Patients
|
||
| Completed |
NCT03358030 -
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
|
Phase 2 | |
| Recruiting |
NCT01415570 -
Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD)
|
N/A | |
| Completed |
NCT00548249 -
Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
|
Phase 2 |